QS Investors LLC grew its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 36.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 378,570 shares of the biopharmaceutical company’s stock after acquiring an additional 101,018 shares during the period. QS Investors LLC owned about 0.28% of Achillion Pharmaceuticals worth $1,738,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Achillion Pharmaceuticals by 3.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 800 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Achillion Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock valued at $2,100,000 after acquiring an additional 2,850 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Achillion Pharmaceuticals by 6.4% in the second quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 3,410 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Achillion Pharmaceuticals by 1.8% in the second quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 3,827 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 4,144 shares in the last quarter. 74.11% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently weighed in on ACHN shares. Ladenburg Thalmann Financial Services lowered their target price on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 14th. BidaskClub cut shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Chardan Capital reduced their price objective on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Wednesday, August 9th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $4.00 price objective (down previously from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $6.75.

TRADEMARK VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/10/qs-investors-llc-has-1-74-million-stake-in-achillion-pharmaceuticals-inc-achn.html.

Achillion Pharmaceuticals, Inc. (ACHN) opened at 4.70 on Tuesday. The firm’s 50-day moving average is $4.48 and its 200-day moving average is $4.24. The firm’s market cap is $642.78 million. Achillion Pharmaceuticals, Inc. has a 12 month low of $3.15 and a 12 month high of $7.95.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). During the same quarter in the prior year, the business posted ($0.14) EPS. Equities analysts expect that Achillion Pharmaceuticals, Inc. will post ($0.66) earnings per share for the current year.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Stock Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.